Special Issue "Translational Research in Gastric Cancer Surgery: Current Status and Future Perspectives of Multimodal Treatment Approach"

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".

Deadline for manuscript submissions: 15 August 2023 | Viewed by 1528

Special Issue Editors

Prof. Dr. Luigi Marano
E-Mail Website
Guest Editor
Department of Medicine, Surgery and Neurosciences, Unit of General Surgery and Surgical Oncology, University of Siena, Siena, Italy
Interests: gastric cancer; robotic surgery; histopathological aspects; signet ring cells; lymphadenectomy; molecular classifications; peritoneal spreading; neoadjuvant chemotherapy; esophageal cancer; achalasia; reflux disease
Special Issues, Collections and Topics in MDPI journals
Dr. Ludovico Carbone
E-Mail Website
Co-Guest Editor
Department of Medicine, Surgery and Neurosciences, Unit of General Surgery and Surgical Oncology, University of Siena, Siena, Italy
Interests: gastric cancer; histopathological aspects; signet ring cells; lymphadenectomy; molecular classifications; peritoneal spreading; neoadjuvant chemotherapy; esophageal cancer; achalasia; reflux disease
Prof. Dr. Franco Roviello
E-Mail Website
Co-Guest Editor
Department of Medicine, Surgery and Neurosciences, Unit of General Surgery and Surgical Oncology, University of Siena, Siena, Italy
Interests: gastric cancer; robotic surgery; histopathological aspects; lymphadenectomy; molecular classifications; peritoneal spreading; neoadjuvant chemotherapy; conversion surgery; cytoreductive surgery; hereditary diffuse gastric cancer

Special Issue Information

Dear Colleagues,

Despite significant improvements in medical as well surgical technologies over the last two decades, the prognosis of patients with gastric adenocarcinoma remains poor. It is well known that gastric cancer is not a single disease but a conglomerate of histologically, biologically and genetically heterogeneous diseases, conditioned by gradual accumulation of various genetic and epigenetic alterations leading to the activation of several molecular pathways resulting in a markedly different responses to the same treatment. High-quality research and advances in technology have contributed to the discovery of molecular pathways as well as histopathologic aspects underlying disease progression and have stimulated many clinical studies testing tailored managements.

Actually, it appears essential to classify tumors based on the underlying oncogenic pathways and to develop genotype-based molecular therapies acting on individual tumors, deeply redefining the natural history of gastric cancer and establishing a new standard for diagnostic, staging and therapeutic tools aiming at a “precision medicine” approach.

We invite researchers to contribute to this Special Issue with high-quality original papers, as well as  review articles, focusing on the development and validation of biomarkers to optimize patient selection and treatment strategies.

Prof. Dr. Luigi Marano
Dr. Ludovico Carbone
Prof. Dr. Franco Roviello
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastric cancer
  • histopathologicaly
  • molecular classifications
  • neoadjuvant chemotherapy
  • conversion surgery
  • translational research

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment
Curr. Oncol. 2022, 29(7), 4868-4878; https://doi.org/10.3390/curroncol29070386 - 11 Jul 2022
Viewed by 1163
Abstract
Background: Therapeutic options in metastatic esophageal cancer (EC) are limited with unsatisfactory results. We evaluated the efficacy of regional chemotherapy (RegCTx) approach in diffuse metastatic EC using arterial infusion (AI), upper abdominal perfusion (UAP) and isolated-thoracic perfusion (ITP) in 14 patients (N = [...] Read more.
Background: Therapeutic options in metastatic esophageal cancer (EC) are limited with unsatisfactory results. We evaluated the efficacy of regional chemotherapy (RegCTx) approach in diffuse metastatic EC using arterial infusion (AI), upper abdominal perfusion (UAP) and isolated-thoracic perfusion (ITP) in 14 patients (N = 8 adenocarcinoma (AC) and N = 6 squamous cell carcinoma (SQCC)) after failure to first-line palliative treatment. Methods: All patients had previously failed first-line palliative treatment attempt with systemic chemotherapy (sCTx). In total 51 RegCTx cycles (12 AI, 3 UAP and 36 ITP) were applied using cisplatin, Adriamycin and Mitomycin C. The outcome was evaluated using RECIST criteria with MediasStat 28.5.14 and SPSS–28.0. Results: No grade III or IV hematological complications occurred. The overall response rate was 41% partial response, 27% stable and 32% progressive disease. Median overall survival (OS) was 38 months (95%CI 10.1–65.9). The OS was better in SQCC with 51 months The RegCTx specific survival was 13 months (95%CI 2.9–23.1) in the entire cohort and 25 months in SQCC patients. Conclusion: RegCTx is a valuable safe approach and superior to the current proposed therapeutic options in metastatic EC after failure to first-line therapy. Full article
Show Figures

Figure 1

Back to TopTop